KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Total Liabilities (2019 - 2025)

Ginkgo Bioworks Holdings' Total Liabilities history spans 7 years, with the latest figure at $611.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 7.6% year-over-year to $611.1 million; the TTM value through Dec 2025 reached $611.1 million, down 7.6%, while the annual FY2025 figure was $611.1 million, 7.6% down from the prior year.
  • Total Liabilities reached $611.1 million in Q4 2025 per DNA's latest filing, down from $629.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $809.6 million in Q1 2023 to a low of $150.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $586.1 million, with a median of $614.6 million recorded in 2025.
  • Peak YoY movement for Total Liabilities: skyrocketed 203.16% in 2021, then fell 29.25% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $503.6 million in 2021, then soared by 59.46% to $803.0 million in 2022, then dropped by 29.25% to $568.2 million in 2023, then grew by 16.4% to $661.4 million in 2024, then fell by 7.6% to $611.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Total Liabilities are $611.1 million (Q4 2025), $629.4 million (Q3 2025), and $618.1 million (Q2 2025).